What is NA-931, a quadruple receptor agonist ?
NA-931 is the first in class, a quadruple receptors agonist of IGF-1, GLP-1, GIP and Glucagon.
NA-931 is the first ORAL medicine is designed for the treatment of obesity that enables weight loss without many adverse events associated with GLP-1 drugs.
NA-931 has been developed for chronic weight management in adults with a body mass index (BMI) of 30 kg/m² or greater (obesity) or 27 kg/m² or greater (overweight) with at least one weight-related comorbid condition (e.g., hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease).
HOW DOES IT WORK?
NA-931™, a quadruple receptor agonist, has demonstrated a proof of efficacy and safety for potential treatment of obesity. NA-931 regulates the homeostasis of IGF-1, GLP-1, GIP and Glucagon to facilitate weight loss without many of the adverse events associated with current obesity drugs.
* NA-931 can easily cross the blood brain barrier, so only a small dose of the drug is required to be effective.
* NA-931 regulates IGF-1, GLP-1 and GIP and Glucagon
* It has great bioavailability in the body
* NA-931 is safe and well tolerated, with no serious adverse events observed
* It has been shown to significantly reduce the body mass index, without muscle loss
* NA-931 is available in oral formulation: convenient for patient to take one capsule once a day.
NA-931 has succefully completed Phase 2 clinical trials. NA-931 not only significantly reduces body fat but also preserves muscle mass. Furthermore, NA-931 exhibits a notable reduction in adverse events commonly associated with existing treatments.
1. Receptor Targeting
Traditional GLP 1 drugs (like semaglutide, liraglutide, exenatide) activate only the GLP 1 receptor.
NA 931 is a quadruple agonist—meaning it simultaneously targets GLP 1, GIP, glucagon, and IGF 1 receptors. This multi-pathway approach is a significant advancement over first-generation GLP 1-only agents.
2. Mode of Delivery
Most current GLP 1 medications require subcutaneous injection (daily or weekly).
NA-931 is designed as an oral, once daily capsule, taken without the need for harsh absorption enhancers.
3. Pharmacokinetics
Injectables like semaglutide have long half-lives (around 165–184 hours), allowing for once-weekly dosing.
NA-931 has an estimated half-life of 16–24 hours, supporting its once-daily oral administration.
4. Clinical Status & Potential Benefits
GLP 1 drugs like semaglutide are FDA-approved for type 2 diabetes and, in certain formulations, for weight loss.
NA-931 has successfully completed Phase 2 and is currently in Phase 3 clinical trials for type 2 diabetes, obesity, and related metabolic disorders.
Phase 2 clinical data of findings indicate it may reduce body fat while preserving muscle mass (thanks to the mechanism of action of IGF-1).
5. What are advantages of NA-931’s quadruple receptor agonism?
The unique advantage of targeting GLP-1, GIP, glucagon, and IGF-1—is that it helps achieve a more natural balance (homeostasis) between energy intake, energy expenditure, satiety, and appetite regulation.
By engaging multiple metabolic pathways simultaneously, it more closely mimics the body’s own regulatory mechanisms. This integrated action not only enhances weight and glucose control but also contributes to fewer adverse effects compared with single- or dual-receptor drugs, since the workload is distributed across complementary biological systems rather than overloading a single pathway.
Phase 2 Clinical Trials Results of NA-931, a Novel Quadruple IGF-1-1, GLP-1, GIP, and Glucagon Receptor Agonist Reduces Body Weight without Muscle Loss
LLOYD L. TRAN et al- Publication is pending
Phase 2 Clinical Trials Results of NA-931, a Novel Quadruple IGF-1-1, GLP-1, GIP, and Glucagon Receptor Agonist Reduces Body Weight without Muscle Loss
LLOYD L. TRAN et al- Publication is pending
NA-931, a Novel Quadruple IGF-1-1, GLP-1, GIP, and Glucagon Receptor Agonist Reduces Body Weight without Muscle Loss
LLOYD L. TRAN; 143-OR: NA-931, a Novel Quadruple IGF-1-1, GLP-1, GIP, and Glucagon Receptor Agonist Reduces Body Weight without Muscle Loss. Diabetes 20 June 2025; 74 (Supplement_1): 143–ORAL PRESENTATION.
https://doi.org/10.2337/db25-143-OR
https://diabetesjournals.org/diabetes/article/74/Supplement_1/143-OR/159475/143-OR-NA-931-a-Novel-Quadruple-IGF-1-1-GLP-1-GIP
Phase 2 Clinical Trials of NA-931 to Study Subjects Who Are Obese with at Least One Weight-Related Comorbid Condition
LLOYD L. TRAN; 2189-LB: Phase 2 Clinical Trials of NA-931 to Study Subjects Who Are Obese with at Least One Weight-Related Comorbid Condition. Diabetes 20 June 2025; 74 (Supplement_1): 2189–LB.
https://doi.org/10.2337/db25-2189-LB
https://diabetesjournals.org/diabetes/article/74/Supplement_1/2189-LB/160162/2189-LB-Phase-2-Clinical-Trials-of-NA-931-to-Study
July 17, 2025
June 23, 2025
May 5, 2025
January 16, 2025
December 10, 2024
November 4, 2024
July 1, 2024
June 11, 2024
Biomed’s team recently presented a keynote lecture on “A Novel Quadruple IGF-1, GLP-1, GIP, and Glucagon Receptor Agonist Attenuates Alcohol-Mediated Behavior,” showcased preclinical data on NA-931, originally developed for metabolic disorders such as obesity, the research highlights its potential for treating Alcohol Use Disorder (AUD).
Biomed Industries, Inc. Unveils Groundbreaking research on NA-931 as a Potential Treatment for Alcohol Use Disorder
View press release distributed by EIN Press Access:
https://www.einpresswire.com/article/763705193/biomed-industries-inc-unveils-groundbreaking-research-on-na-931-as-a-potential-treatment-for-alcohol-use-disorder?n=2
Preclinical studies demonstrate that NA-931 significantly attenuates alcohol-induced locomotor stimulation while reducing alcohol intake and alcohol-seeking behaviors in animal models. These results position NA-931 as a promising therapeutic candidate for AUD.
A key advantage of NA-931 is its oral formulation, which offers a more favorable safety profile compared to existing GLP-1-based therapies.
According to the 2023 National Survey on Drug Use and Health (NSDUH), 28.9 million Americans aged 12 and older experienced AUD. Globally, the World Health Organization estimates that AUD affects 400 million people, representing approximately 7% of the population aged 15 and older.
The AUD treatment market reflects the significant growth seen in the obesity drug market. In 2017, the global obesity market was valued at $1.3 billion. Following the introduction of GLP-1-based weight loss therapies, the market is projected to surpass $100 billion in the next five years. Similarly, the AUD drug market, valued at $667 million in 2023, presents immense growth potential as innovative treatments like NA-931 advance.
View a selected list of PUBLICATIONS and PRESENTATIONS at CONFERENCES
For further information about our products, please contact us. Contact us